KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$6.5 million.

  • Neogenomics' Free Cash Flow fell 26286.83% to -$6.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$21.8 million, marking a year-over-year increase of 3601.86%. This contributed to the annual value of -$21.8 million for FY2025, which is 3601.86% up from last year.
  • According to the latest figures from Q4 2025, Neogenomics' Free Cash Flow is -$6.5 million, which was down 26286.83% from $570000.0 recorded in Q3 2025.
  • Neogenomics' Free Cash Flow's 5-year high stood at $14.0 million during Q2 2025, with a 5-year trough of -$37.3 million in Q1 2022.
  • In the last 5 years, Neogenomics' Free Cash Flow had a median value of -$11.7 million in 2021 and averaged -$13.7 million.
  • As far as peak fluctuations go, Neogenomics' Free Cash Flow plummeted by 62318.7% in 2021, and later soared by 162076.17% in 2025.
  • Over the past 5 years, Neogenomics' Free Cash Flow (Quarter) stood at -$31.8 million in 2021, then surged by 74.12% to -$8.2 million in 2022, then skyrocketed by 230.51% to $10.7 million in 2023, then plummeted by 116.77% to -$1.8 million in 2024, then crashed by 262.87% to -$6.5 million in 2025.
  • Its Free Cash Flow stands at -$6.5 million for Q4 2025, versus $570000.0 for Q3 2025 and $14.0 million for Q2 2025.